Background: Spontaneous regression of thymic carcinoma is extremely rare. We report a case of a resected thymic carcinoma with preoperative spontaneous regression in a 67-year-old woman.
Case Presentation: The patient presented with low-grade fever and anterior chest pain. Chest computed tomography (CT) showed a 55 × 43 mm exophytic heterogeneously enhancing mass showing some areas of necrosis. Chest CT done one day preoperatively revealed that the tumor had rapidly shrunk for one month. Surgical resection was performed to obtain a definitive diagnosis and achieve complete resection, yielding a postoperative diagnosis of thymic carcinoma. The patient survived without signs of recurrence for 12 months postoperatively.
Conclusions: Mediastinal tumors with necrosis demonstrating spontaneous regression should include thymic carcinomas in the differential diagnosis.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9374853 | PMC |
| http://dx.doi.org/10.1186/s40792-022-01510-w | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
GTF2I acts as a novel tumor suppressor transcription factor and shows Favorable prognosis in renal cancer.
Integr Biol (Camb)
January 2025
Manipal Academy of Higher Education (MAHE), Manipal 576104, Karnataka, India.
The role of GTF2I (General Transcription Factor2I) alteration has already been reported in thymic cancer as a valuable biomarker. However, the association of GTF2I mutation with renal cancer for prognosis of immunotherapy is not yet examined. The biologic and oncologic significance of GTF2I in renal cancer was examined at multiomics level such as mutation, copy number alteration, structural variants.
View Article and Find Full Text PDFThe Role of [F]F-FDG PET/CT for Predicting Histology and Prognosis in Patients with Thymic Lesions.
Mol Diagn Ther
January 2025
Thoracic Surgery and Lung Transplantation, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, 20122, Milan, Italy.
Objectives: To investigate whether 18F-fluorodeoxyglucose positron emission tomography-computed tomography ([F]F-FDG PET/CT) metabolic parameters were associated with histology and to assess their prognostic role in patients with thymic lesions.
Patients And Methods: In total, 116 patients (49/67 M/F; mean age 59.5 years) who underwent preoperative [F]F-FDG PET/CT and thymectomy from 2012 to 2022 were retrospectively analyzed.
Multimodal management and complete resection of invasive Type B3 thymoma with vascular reconstruction: a case report.
J Cardiothorac Surg
January 2025
Department of Thoracic Surgery, Guy's and St Thomas' NHS Foundation Trust, London, England.
Introduction: Thymomas and thymic carcinomas are rare anterior mediastinal tumours, accounting for 0.2-1.5% of all cancers.
View Article and Find Full Text PDFIDEAL-IQ Magnetic Resonance Imaging Fat Fraction Quantification in Distinguishing Thymic Hyperplasia From Low-Risk Thymoma and Thymic Lymphoma in Adulthood: A Reliability and Efficacy Analysis.
J Comput Assist Tomogr
November 2024
From the Department of Radiology & Functional and Molecular Imaging Key Lab of Shaanxi Province.
Objectives: Detection of fat content in thymic lesions is essential to differentiate thymic hyperplasia from thymic tumors. This study assesses the reliability and efficacy of "iterative decomposition of water and fat with echo asymmetry and least-squares estimation quantization" IDEAL-IQ magnetic resonance sequence in distinguishing thymic hyperplasia from low-risk thymoma and thymic lymphoma in adulthood.
Methods: Thirty patients with thymic hyperplasia, 28 low-risk thymomas, and 13 thymic lymphomas were respectively enrolled.
Phase II Parallel Arm Study of Sacituzumab Govitecan-Hziy in Patients With Advanced Thymoma or Thymic Carcinoma.
Clin Lung Cancer
December 2024
Georgetown University, Washington, DC. Electronic address:
Background: Thymic epithelial tumors (TETs), including thymoma and thymic carcinoma, are rare thoracic tumors of the anterior mediastinum. For those with advanced disease, platinum-based chemotherapy is used as first-line treatment. However, there is no standard regimen established for TET at progression after initial therapy, and treatment options for advanced/recurrent TETs are limited.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!